Contemporary treatment of APL.

Abstract:

:Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and maintenance therapy. This general treatment approach has resulted in cure rates of 80-90 %. ATO, originally approved in relapsed APL, has been incorporated into contemporary upfront treatment regimens with excellent response rates. Recent studies show that most patients with APL can be cured with ATRA and ATO alone, eliminating cytotoxic chemotherapy and resulting in superior outcomes compared to standard treatment. We will herein review historical treatment of APL, treatment considerations in specific patient populations, and therapeutic updates.

journal_name

Curr Hematol Malig Rep

authors

Cull EH,Altman JK

doi

10.1007/s11899-014-0205-6

subject

Has Abstract

pub_date

2014-06-01 00:00:00

pages

193-201

issue

2

eissn

1558-8211

issn

1558-822X

journal_volume

9

pub_type

杂志文章,评审
  • Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

    abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-009-0028-z

    authors: Kahl BS

    更新日期:2009-10-01 00:00:00

  • Choosing Wisely® in Hematology: Have We Made a Difference?

    abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00593-2

    authors: Hilal T,Munoz J

    更新日期:2020-08-01 00:00:00

  • Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

    abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0129-y

    authors: Casasnovas RO,Meignan M,Berriolo-Riedinger A,Itti E,Huglo D,Haioun C,Morschhauser F

    更新日期:2012-09-01 00:00:00

  • Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

    abstract:PURPOSE OF REVIEW:To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs)....

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0459-5

    authors: Chander U,Leeman-Neill RJ,Bhagat G

    更新日期:2018-08-01 00:00:00

  • The Management of Lymphoma in the Setting of Pregnancy.

    abstract::The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0386-x

    authors: Pinnix CC,Andraos TY,Milgrom S,Fanale MA

    更新日期:2017-06-01 00:00:00

  • Update on antigen-specific immunotherapy of acute myeloid leukemia.

    abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0250-9

    authors: Buckley SA,Walter RB

    更新日期:2015-06-01 00:00:00

  • Recognizing unusual manifestations of Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0131-4

    authors: Barber NA,Bierman PJ

    更新日期:2012-09-01 00:00:00

  • Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

    abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0283-0

    authors: Karp Leaf R,Cho HJ,Avigan D

    更新日期:2015-12-01 00:00:00

  • Chemotherapy for patients with acute myeloid leukemia in first remission.

    abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-006-0021-8

    authors: Bradstock K

    更新日期:2006-06-01 00:00:00

  • Incorporating novel agents in the management of elderly myeloma patients.

    abstract::In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and in...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-013-0177-y

    authors: Guglielmelli T,Palumbo A

    更新日期:2013-12-01 00:00:00

  • An immune dysregulation in MPN.

    abstract::Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-014-0227-0

    authors: Barosi G

    更新日期:2014-12-01 00:00:00

  • Frailty in Hematologic Malignancy.

    abstract:PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0454-x

    authors: Koll TT,Rosko AE

    更新日期:2018-06-01 00:00:00

  • High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    abstract::Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-009-0035-0

    authors: Gergis U,Wissa U

    更新日期:2010-01-01 00:00:00

  • Role of autologous stem cell transplantation in multiple myeloma.

    abstract::High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-007-0017-z

    authors: Kumar S

    更新日期:2007-05-01 00:00:00

  • Lenalidomide in myelodysplastic syndromes: where do we go from here?

    abstract::Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-008-0002-1

    authors: Sirulnik LA,Stone RM

    更新日期:2008-01-01 00:00:00

  • Role of minimal residual disease evaluation in leukemia therapy.

    abstract::In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-008-0022-x

    authors: Campana D

    更新日期:2008-07-01 00:00:00

  • The role of parenteral nutrition in acute leukemia.

    abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-996-0007-6

    authors: Jacobson NB,Parekh N,Kalaycio M

    更新日期:2006-09-01 00:00:00

  • Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.

    abstract:PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0449-7

    authors: Kennedy JA,Hobbs G

    更新日期:2018-06-01 00:00:00

  • Cutaneous T-cell lymphoma: Biologic targets for therapy.

    abstract::Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-007-0037-8

    authors: Choi J,Foss F

    更新日期:2007-10-01 00:00:00

  • Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    abstract::The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0273-2

    authors: Roberts DA,Steensma DP

    更新日期:2015-09-01 00:00:00

  • Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

    abstract::Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0369-y

    authors: Sethi TK,Basdag B,Bhatia N,Moslehi J,Reddy NM

    更新日期:2017-06-01 00:00:00

  • Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

    abstract::Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0140-3

    authors: Steensma DP

    更新日期:2012-12-01 00:00:00

  • The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.

    abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00596-z

    authors: Patel AA,Odenike O

    更新日期:2020-12-01 00:00:00

  • New aspects of the treatment of chronic lymphocytic leukemia.

    abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-006-0006-7

    authors: Faderl S,Wierda W,Keating MJ

    更新日期:2006-12-01 00:00:00

  • Targeting chronic myeloid leukemia stem cells.

    abstract::Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-010-0043-0

    authors: Helgason GV,Young GA,Holyoake TL

    更新日期:2010-04-01 00:00:00

  • Genetic basis of MPN: Beyond JAK2-V617F.

    abstract::The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-013-0184-z

    authors: Them NC,Kralovics R

    更新日期:2013-12-01 00:00:00

  • A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.

    abstract:PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-021-00604-w

    authors: Epperla N,Hamadani M

    更新日期:2021-01-25 00:00:00

  • Assessing Quality of Care for the Myelodysplastic Syndromes.

    abstract::Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-016-0343-0

    authors: Frosch ZA,Abel GA

    更新日期:2016-12-01 00:00:00

  • Primary mediastinal large B-cell lymphoma.

    abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-014-0219-0

    authors: Dabrowska-Iwanicka A,Walewski JA

    更新日期:2014-09-01 00:00:00

  • Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.

    abstract::C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-013-0193-y

    authors: Callejas-Díaz A,Gea-Banacloche JC

    更新日期:2014-03-01 00:00:00